Latest papers

Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain.

Amyloid-beta vaccination for Alzheimer's dementia.

Amyloid-beta immunisation for Alzheimer's disease.

Edible tools to fight Alzheimer's.

The vaccines development forum.

[The lesions of Alzheimer's disease: which therapeutic perspectives?].

[Alzheimer's disease: from brain lesions to new drugs]

[Alzheimer's disease: therapeutic perspectives].

[Therapy of Alzheimer's disease: current status and future development].

Successful adjuvant-free vaccination of BALB/c mice with mutated amyloid beta peptides.

Complexities of Clinical Assay Development and Optimization Prior to First-in-Man Immunization Trials – A Description of Immunogenicity Assay Development for the Testing of Samples from a Phase 1 Alzheimer's Vaccine Trial

[Vaccination against Alzheimer's disease?].

Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis.

Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice.

An alternative method for estimating efficacy of the AN1792 vaccine for Alzheimer disease.

Immunotherapy as treatment for Alzheimer's disease.

Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's disease.

Novel Abeta immunogens: is shorter better?

Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice.

The immunology of Alzheimer's disease: prospects towards harnessing disease mechanisms for therapeutic ends.